CC BY 4.0Erkens, FrederikFrederikErkens2022-11-302022-11-302022https://publica.fraunhofer.de/handle/publica/429398https://doi.org/10.24406/publica-57410.24406/publica-574CAR-T Manufacturing suffers from labor intensive manufacturing, biological variability of patient material while inflexible production protocols are employed. To improve the availability of CAR-T therapies to patient the AIDPATH EU-Project aims to develop build and test a modular decentralized manufacturing system for CAR-T therapy. Automating using a closed handling approach allows for parallelization while the modularity enables broad technological compatibility. Automated sampling for in-line quality control collects large amount of data on the cell samples which are fed in an AI-digital twin of the CAR-T product to support and adapt the manufacturing process. Automating the manufac-turing process and accounting for biological variability is the key to optimize CAR-T cell production.enCAR-TManufacturingAIAutomationpresentation